Vancomycin-resistant enterococcal bacteraemia and daptomycin: Are higher doses necessary?

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 9, 2011, Pages 2112-2118

  King, Esther A ^a   McCoy, Dorothy ^a,b   Desai, Samit ^a   Nyirenda, Themba ^a   Bicking, Keri ^a  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

High dose daptomycin; MICs; VRE

Indexed keywords

DAPTOMYCIN; VANCOMYCIN;

ARTICLE; BACTEREMIA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG MEGADOSE; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; HUMAN; MINIMUM INHIBITORY CONCENTRATION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; DAPTOMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NEUTROPENIA; RETROSPECTIVE STUDIES; TREATMENT FAILURE; TREATMENT OUTCOME; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 80051676875     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr255     Document Type: Article

References (30)

1. CUBICIN (package insert). Lexington, MA: Cubist Pharmaceuticals, Inc., 2008.
2. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Fifteenth Informational Supplement M100-S15. CLSI, Wayne, PA, USA, 2005.
3. Pfaller MA, Sader HS, Jones RN. Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005). Diagn Microbiol Infect Dis 2007; 57: 459-65.
4. Sader HS, Jones RN. Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008). Diagn Microbiol Infect Dis 2009; 65: 158-62.
5. DiazGranados CA, Zimmer SM, Klein M et al. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis 2005; 41: 327-33.
6. Salgado CD, Farr BM. Outcomes associated with vancomycin-resistant enterococci: a meta-analysis. Infect Control Hosp Epidemiol 2003; 24: 690-8.
7. Mohr JF, Friedrich LV, Yankelev S et al. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE). Int J Antimicrob Agents 2009; 33: 543-8.
8. Gallagher JC, Perez ME, Marino EA et al. Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients. Pharmacotherapy 2009; 29: 792-9.
9. Mave V, Garcia-Diaz J, Islam T et al. Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid? J Antimicrob Chemother 2009; 64: 175-80.
10. Locastro LG, Perez ME, Marino EA et al. Comparison of linezolid (LZD) and daptomycin (DAP) for vancomycin-resistant Enterococcus bacteremia (VREB). In: Abstracts of the Forty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2008. Abstract K-3440, p. 538. American Society for Microbiology, Washington, DC, USA.
11. Dubrovaskaya Y, Kubin CJ, Furuya EY. Daptomycin (D) compared to linezolid (L) for primary treatment of vancomycin-resistant enterococcal bacteremia (VREB). In: Abstracts of the Forty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2008. Abstract K-3443, p. 539. American Society for Microbiology, Washington, DC, USA.
12. Hjalmarson KI, Craven DE, Golan Y. The use of daptomycin (dapto) in vancomycin-resistant Enterococcus (VRE) bacteremia: a single center experience. In: Abstracts of the Forty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2008. Abstract K-3439, p. 538. American Society for Microbiology, Washington, DC, USA.
13. Gaffney M, Mckinnon P, Mohr J et al. Clinical experience with daptomycin (DAP) for the treatment of vancomycin-resistant enterococcal bacteremia (VRE-B). In: Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009. Abstract L1-985. American Society for Microbiology, Washington, DC, USA.
14. Rose WE, Rybak MJ, Kaatz GW. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. J Antimicrob Chemother 2007; 60: 334-40.
15. Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 2004; 48: 63-8.
16. Figueroa DA, Mangini E, Amodio-Groton M. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis 2009; 49: 177-80.
17. Moise PA, Hershberger E, Amodio-Groton MI et al. Safety and clinical outcomes when utilizing high-dose (≥8 mg/kg) daptomycin therapy. Ann Pharmacother 2009; 43: 1211-9.
18. Dvorchik BH, Brazier D, DeBruin MF et al. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003; 47: 1318-23.
19. Benvenuto M, Benziger DP, Yankelev S et al. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006; 50: 3245-9.
20. Baddour LM, Wilson WR, Bayer AS et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111: e394-434.
21. Mermel LA, Allon M, Bouza E et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection. Clin Infect Dis 2009; 49: 1-45.
22. Mermel LA, Farr BM, Sherertz RJ et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001; 32: 1249-72.
23. Sakoulas G, Alder J, Thauvin-Eliopoulos C et al. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 2006; 50: 1581-5.
24. Cui L, Iwamoto A, Lian JQ et al. Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 428-38.
25. Cui L, Ma X, Sato K et al. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol 2003; 41: 5-14.
26. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 2001; 1: 147-55.
27. Cui L, Tominaga E, Neoh HM et al. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 1079-82.
28. Moise PA, Smyth DS, El-Fawal N et al. Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2008; 61: 85-90.
29. Rose WE, Leonard SN, Sakoulas G et al. Daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2008; 52: 831-6.
30. Soriano A, Marco F, Martínez JA et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46: 193-200.